The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38

Melissa J LaBonte, Philipp C Manegold, Peter M Wilson, Will Fazzone, Stan G Louie, Heinz-Josef Lenz, Robert D Ladner, Melissa LaBonte Wilson

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science